Pfizer's Ibrance has become the first CDK4/6 inhibitor to be approved by the FDA for a challenging subtype of breast cancer ...

Hundreds of women with aggressive cervical cancer are to be offered MSD's Keytruda on the NHS in England, in the second ...

Earlier this year, when US telehealth giant Hims & Hers first unveiled plans to acquire its Australian rival Eucalyptus for a ...

Around 90 women with advanced cervical cancer in the UK could be eligible for treatment with Regeneron's immunotherapy ...

The US pharmaceutical industry is entering a new phase of supply chain transformation. Regulatory pressure, geopolitical ...

Eli Lilly's LillyDirect sales channel, which has become an important driver of sales of its weight-loss therapies in the US, has now arrived in the UK. LillyDirect operates as a direct-to-patient (DTP ...

Ollin Biosciences has followed its $100 million Series A last year with a massive $330 million second round that will fuel ...

One of the antibody-drug conjugates at the heart of Pfizer's $43 billion acquisition of Seagen three years ago has failed a ...

In a landmark decision for people with early type 1 diabetes (T1D) in the UK, Sanofi's first-of-its-kind therapy Tzield, ...

HHS acknowledged in a statement on Operation Trailblazer that "a growing share of early-stage clinical research has moved ...

Mike Westby, RQ Bio's chief executive. RQ Bio has raised £85.5 million ($115 million) first-round financing, led by Frazier Life Sciences, to support trials of a one-shot antibody designed to protect ...

CARSgen Therapeutics has claimed approval in China, its home market, for satricabtagene autoleucel (satri-cel), said to be ...